Patients with high levels of intratumoral IL-17A cells and low levels of peritumoral IL-17A cells in TNM stages II/III are more likely to benefit from ACT. Elevated IL-17A mRNA expression and increased intratumoral IL-17A cell infiltration are associated with enhanced infiltration of anti-tumor mast cells and natural killer cells, as well as reduced infiltration of pro-tumor M2 macrophages. This evidence concerns the gene IL17A and neoplasm.